Investment Analysts’ Weekly Ratings Updates for Ocular Therapeutix (OCUL)

Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates:

• 2/18/2026 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
• 2/17/2026 – Ocular Therapeutix had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 2/17/2026 – Ocular Therapeutix had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 2/7/2026 – Ocular Therapeutix was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 2/5/2026 – Ocular Therapeutix had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $30.00 price target on the stock.
• 1/22/2026 – Ocular Therapeutix had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Sanjay Nayak sold 10,348 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $93,545.92. Following the sale, the insider owned 332,412 shares of the company’s stock, valued at approximately $3,005,004.48. The trade was a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the sale, the insider owned 3,033,078 shares of the company’s stock, valued at $27,419,025.12. The trade was a 3.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 166,029 shares of company stock valued at $1,498,430. 2.30% of the stock is currently owned by corporate insiders.

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.